GoldenGolden
Advanced Search
DCPrime

DCPrime

DCPrime is a biotechnology company developing cancer immunotherapies.

All edits

Edits on 6 Aug, 2021
Golden AI"Inferring industry - ai.industry_clf.02"
Golden AI edited on 6 Aug, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Biopharmaceutical
Edits on 9 Jun, 2021
Erin Scherfner"prospector:320:158223"
Erin Scherfner edited on 9 Jun, 2021
Edits made to:
Infobox (+2 properties)
Infobox
Edits on 12 May, 2021
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 12 May, 2021
Edits made to:
Article (+5/-5 characters)
Article

DCPrime's vaccine, the DCP-001, is a cell-based vaccine that is designed to fight against blood cancers known for relapsing in a patient. The product is in PhasePhase II clinical trials for the purpose of treating acute myeloid leukemia. The company is primarily focused on developing therapeutic candidates for treating hematological malignancies that have a high risk of relapse, which would allow patients to avoid repeat treatments of chemotherapy or bone marrow transplants. The trials are being evaluated in patients with AML, who have responded to chemotherapy treatment, but cannot undergo bone marrow transplant procedures.

Golden AI"Funding autocalculation"
Golden AI edited on 12 May, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding type
Edits on 29 Mar, 2021
Golden AI"Found on funding round"
Golden AI edited on 29 Mar, 2021
Edits made to:
Infobox (+4 properties)
Infobox
Investors
Edits on 9 Nov, 2020
Daniel Frumkin"added article, infobox items, company, timeline"
Daniel Frumkin edited on 9 Nov, 2020
Edits made to:
Infobox (+4/--2 properties)
Timeline (+2 events) (+126 characters)
Article (+1243 characters)
Table (+1 rows) (+4 cells) (+74 characters)
Article

DCPrime is a company that develops clinical stage, novel cancer immunotherapies that are based on their DCOne platform. The company was founded by Ada Kruisbeek in 2006, in Leiden, Zuid-Holland, The Netherlands.

The company's vaccines are designed for the purpose of relapse, and are designed to be administered after a standard care therapy. The relapse vaccine is used for the purpose of reinforcing a patient's immune system while it is healthy.

DCPrime's vaccine, the DCP-001, is a cell-based vaccine that is designed to fight against blood cancers known for relapsing in a patient. The product is in Phase II clinical trials for the purpose of treating acute myeloid leukemia. The company is primarily focused on developing therapeutic candidates for treating hematological malignancies that have a high risk of relapse, which would allow patients to avoid repeat treatments of chemotherapy or bone marrow transplants. The trials are being evaluated in patients with AML, who have responded to chemotherapy treatment, but cannot undergo bone marrow transplant procedures.

The company signed a licensing agreement with Glycotope in order to combine and advance their cancer vaccination and therapeutic antibody platforms in September of 2020.

Table

Company
CEO
Location
Products/Services

DCPrime

Erik Manting

Leiden, Zuid-Holland, The Netherlands

Immunotherapeutics

Infobox
Company status
Active
Email address
info@dcprime.nl
Full address
Galileïweg 8 2333 BD Leiden The Netherlands
Number of Employees (ranges)
20 – 49
Phone number
+31 71 3322627
Timeline

November 5, 2020

DCPrime presents Interim Clinical Data of adVANCE II Trial at ASH 2020 Meeting

September 21, 2020

DCPrime and Glycotope sign a licensing agreement
Edits on 6 Oct, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 6 Oct, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Latest funding round date
March 26, 2018
Edits on 25 Aug, 2020
Golden AI
Golden AI edited on 25 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Products
Golden AI
Golden AI edited on 25 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Products
Aleksander Holm
Aleksander Holm edited on 25 Aug, 2020
Edits made to:
Infobox (--2 properties)
Infobox
Business model
Commerce
Edits on 31 Jul, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
25,980,000
Golden AI
Golden AI edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Edits on 31 Jul, 2020
Lax Mariappan
Lax Mariappan edited on 31 Jul, 2020
Edits made to:
Infobox (+1 properties)
Edits on 28 Jul, 2020
Marie Gabrielle Laguna- Bedia
Marie Gabrielle Laguna- Bedia edited on 28 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 27 Jul, 2020
Lax Mariappan
Lax Mariappan edited on 27 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
2006
Edits on 21 Jul, 2020
Dawson Sewell
Dawson Sewell edited on 21 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.